S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
66,000% upside on tiny biotech? (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Oil tanker breaks down in Egypt's Suez Canal, disrupting traffic in the global waterway
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
With oil prices slumping, OPEC+ producers weigh more production cuts
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
NASDAQ:LPTX

Leap Therapeutics (LPTX) Stock Forecast, Price & News

$0.88
-0.05 (-5.38%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.83
$0.95
50-Day Range
$0.29
$0.93
52-Week Range
$0.27
$1.86
Volume
1.40 million shs
Average Volume
1.51 million shs
Market Capitalization
$105.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.80

Leap Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
218.2% Upside
$2.80 Price Target
Short Interest
Bearish
9.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.57) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.52 out of 5 stars

Medical Sector

882nd out of 983 stocks

Pharmaceutical Preparations Industry

442nd out of 486 stocks


LPTX stock logo

About Leap Therapeutics (NASDAQ:LPTX) Stock

Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. The company was founded on January 3, 2011 and is headquartered in Cambridge, MA.

Receive LPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Leap Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LPTX Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Leap Therapeutics (LPTX) Receives a Buy from Mizuho Securities
Why 2023 Could Kick Off a "Cash Frenzy" in Stocks
But the analyst who called the Lehman Collapse says to expect a "Cash Frenzy" instead.
Leap Therapeutics, Inc. (NASDAQ:LPTX) Short Interest Update
What 5 Analyst Ratings Have To Say About Leap Therapeutics
Leap Therapeutics (NASDAQ:LPTX) Announces Earnings Results
Mizuho Securities Remains a Buy on Leap Therapeutics (LPTX)
Robert W. Baird Keeps Their Buy Rating on Leap Therapeutics (LPTX)
Leap Therapeutics, Inc. (LPTX)
See More Headlines

LPTX Price History

LPTX Company Calendar

Last Earnings
5/15/2023
Today
6/04/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LPTX
Fax
N/A
Employees
36
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$2.80
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+218.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-54,600,000.00
Pretax Margin
-14,214.93%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$0.24 per share

Miscellaneous

Free Float
104,485,000
Market Cap
$105.08 million
Optionable
Not Optionable
Beta
0.67

Key Executives

  • Doug E. Onsi
    President, CEO, CFO, Secretary & Treasurer
  • Augustine J. Lawlor
    Chief Operating Officer
  • Cynthia Sirard
    Chief Medical Officer
  • Jason S. Baum
    Chief Scientific Officer
  • Michael Haas
    Head-Research













LPTX Stock - Frequently Asked Questions

Should I buy or sell Leap Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LPTX shares.
View LPTX analyst ratings
or view top-rated stocks.

What is Leap Therapeutics' stock price forecast for 2023?

3 brokers have issued 12 month price targets for Leap Therapeutics' shares. Their LPTX share price forecasts range from $2.00 to $4.00. On average, they expect the company's share price to reach $2.80 in the next year. This suggests a possible upside of 218.2% from the stock's current price.
View analysts price targets for LPTX
or view top-rated stocks among Wall Street analysts.

How have LPTX shares performed in 2023?

Leap Therapeutics' stock was trading at $0.45 at the start of the year. Since then, LPTX shares have increased by 95.6% and is now trading at $0.88.
View the best growth stocks for 2023 here
.

When is Leap Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our LPTX earnings forecast
.

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics, Inc. (NASDAQ:LPTX) announced its quarterly earnings data on Monday, May, 15th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.09) by $0.23.

What other stocks do shareholders of Leap Therapeutics own?
What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Baker BROS. Advisors LP (6.22%), Samsara BioCapital LLC (5.61%), Price T Rowe Associates Inc. MD (1.29%), Key Client Fiduciary Advisors LLC (1.29%), Knott David M Jr (0.47%) and Renaissance Technologies LLC (0.38%).
View institutional ownership trends
.

How do I buy shares of Leap Therapeutics?

Shares of LPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $0.88.

How much money does Leap Therapeutics make?

Leap Therapeutics (NASDAQ:LPTX) has a market capitalization of $105.08 million and generates $1.50 million in revenue each year. The company earns $-54,600,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The official website for the company is www.leaptx.com. The company can be reached via phone at (617) 714-0360 or via email at heather@argotpartners.com.

This page (NASDAQ:LPTX) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -